{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:56:08Z","timestamp":1789480568053,"version":"build-2803163510"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Paraneoplastic pemphigus (PNP) is a rare life-threatening disease which always associated with an underlying neoplasm. Tumor-related PNP most commonly precedes the detection of a hematological malignancy, with some cases seen during disease remission following cytotoxic drug therapy or radiotherapy. The lung is the most frequently-involved site in PNP, second only to the eyes, and involvement is seen in 59.2% to 92.8% of PNP cases. Bronchiolitis obliterans (BO) is the end stage of respiratory involvement and is regarded as life-threatening. The key point in treatment of PNP is to control the associated underlying hematologic neoplasia. High-dose systemic corticosteroids combined with other immunosuppressants are considered the first line of treatment. Other therapies that have shown beneficial effects include plasmapheresis, intravenous immunogloblin (IVIG), and more recently, daclizumab, alemtuzumab, and rituximab. There is no effective treatment for BO with PNP, and suppression of the cellular immune response may be necessary. Patients with PNP-BO associated with lymphoma mostly die within approximately 1\u2009year. Herein, we reported a patient who diagnosed with PNP-BO concurrent with chronic lymphocytic leukemia. He was successful treated with ibrutinib and had achieved the longest survival which suggested that ibrutinib may be the best treatment choice for such patient.<\/jats:p>","DOI":"10.3389\/fmed.2023.1132535","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T04:50:16Z","timestamp":1678855816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL"],"prefix":"10.3389","volume":"10","author":[{"given":"Can","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenxian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.ad.2017.04.024","article-title":"Paraneoplastic pemphigus. A life-threatening autoimmune blistering disease","volume":"108","author":"Tirado-S\u00e1nchez","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1365-4632.2009.03995.x","article-title":"Paraneoplastic pemphigus\/paraneoplastic autoimmune multiorgan syndrome","volume":"48","author":"Sehgal","year":"2009","journal-title":"Int J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/JID.2015.408","article-title":"Epiplakin is a Paraneoplastic pemphigus autoantigen and related to bronchiolitis obliterans in Japanese patients","volume":"136","author":"Tsuchisaka","year":"2016","journal-title":"J Invest Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(04)15539-6","article-title":"Castleman\u2019s tumours and production of autoantibody in paraneoplastic pemphigus","volume":"363","author":"Wang","year":"2004","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJM200307243490421","article-title":"CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman\u2019s disease","volume":"349","author":"Hoffman","year":"2003","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1183\/09031936.00052806","article-title":"Bronchiolitis obliterans following haematopoietic stem cell transplantation","volume":"29","author":"Soubani","year":"2007","journal-title":"Eur Respir J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.healun.2015.03.021","article-title":"MicroRNA-144 dysregulates the transforming growth factor-\u03b2 signaling cascade and contributes to the development of bronchiolitis obliterans syndrome after human lung transplantation","volume":"34","author":"Xu","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.ajpath.2012.07.021","article-title":"Critical role of VEGF-C\/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis","volume":"181","author":"Krebs","year":"2012","journal-title":"Am J Pathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00428-010-0949-x","article-title":"Obliterative airway remodelling in transplanted and non-transplanted lungs","volume":"457","author":"Jonigk","year":"2010","journal-title":"Virchows Arch"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.healun.2016.06.001","article-title":"Imatinib ameliorates bronchiolitis obliterans via inhibition of fibrocyte migration and differentiation","volume":"36","author":"Watanabe","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJM199905063401805","article-title":"The mechanism of respiratory failure in paraneoplastic pemphigus","volume":"340","author":"Nousari","year":"1999","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J Clin Invest"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1132535\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T04:50:18Z","timestamp":1678855818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1132535\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":15,"alternative-id":["10.3389\/fmed.2023.1132535"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1132535","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"article-number":"1132535"}}